Bacchus Venture Capital — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

InGelingeltx.com inJul 2022

InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous.

BiotechDeep TechHealthtechCambridge, US

Patrick Jiang(CEO & Co-founder)inPierre Colombe Dromel(Chief Technology Officer & Co-founder)inDeepti Singh(Chief Scientific Officer & Co-founder)inMyron Spector(Director)Michael Young(Director)

Co-investorsGaingels Icebook Investments Corp.MassVentures Service Provider Capital The Venture Collective ZAKA VC

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.